Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides/Sézary syndrome; a single-center experience.

Autor: Jfri A; Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts., Virgen CA; Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Tawa M; Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Giobbie-Hurder A; Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Kupper TS; Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Fisher DC; Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., LeBoeuf NR; Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Larocca C; Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts. Electronic address: CLarocca@BWH.Harvard.edu.
Jazyk: angličtina
Zdroj: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2023 Nov; Vol. 89 (5), pp. 1044-1047. Date of Electronic Publication: 2023 Jun 13.
DOI: 10.1016/j.jaad.2023.05.082
Abstrakt: Competing Interests: Conflicts of interest T.S.K. is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR065807 and T32 AR007098) and the National Institute of Allergy and Infectious Diseases (grant number R01 AI127654). He is a scientific advisor for Pellis Therapeutics. N.R.L. is a consultant and has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback and Synox Therapeutics outside the submitted work. C.L. is supported by the National Cancer Institute (grant number R37 CA252312). She has served on a medical advisory board for Kyowa Kirin. The other authors declare no conflicts of interest with respect to the research, authorship and/or publication of this article.
Databáze: MEDLINE
Externí odkaz: